BioGeneration Ventures | Activity | F4BioGeneration Ventures Activity
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Podcast
Managing Partner Edward van Wezel was featured on The BioHub Podcast.
Edward van Wezel on The BioHub Podcast
Portfolio company Phosphoenix secured €1.3 million in financing to advance its visual neuroprosthetic technology toward a first-in-human study.
News
BioGeneration Ventures published its Impact & ESG Report 2025.
BGV Impact & ESG Report 2025
Milestone
Portfolio company Tanai Therapeutics appointed Josua Jordi as Chief Executive Officer.
Tanai Therapeutics
Investment
Portfolio company Mironid raised $46 million in Series B financing to advance clinical development of its rare kidney disease treatment.
Mironid
Milestone
Portfolio company Azafaros completed enrollment of its Phase 3 NAVIGATE study evaluating nizubaglustat for GM1/GM2 gangliosidoses.
Azafaros
Milestone
Portfolio company TargED announced first patients successfully dosed in its study of TGD001 in acute ischemic stroke.
TargED Biopharmaceuticals
Investment
Portfolio company TargED raised a €40.4M Series A2 to advance its first-in-class targeted thrombolytic TGD001.
TargED Biopharmaceuticals
Team Change
General Partner Daniela Couto was elected to the Invest Europe Board.
Daniela Couto elected to Invest Europe Board
Milestone
Portfolio company Confo Therapeutics announced encouraging preclinical data for its post-bariatric hypoglycemia candidate CFTX-2034 at ENDO 2026.
Confo Therapeutics
Podcast
Managing Partner Edward van Wezel was featured on The Clinical Trials Guru.
Edward van Wezel on The Clinical Trials Guru
New Fund
BioGeneration Ventures closed the FIRST II fund to accelerate Dutch life science spinouts in chronic diseases.
FIRST II fund
Team Change
BGV appointed Peter Halle, PhD, as Venture Partner.
Peter Halle appointed Venture Partner
Team Change
BGV appointed Dr. Markus Kalousek and Dr. Andrew Lightfoot as Venture Partners.
Dr. Markus Kalousek and Dr. Andrew Lightfoot join as Venture Partners